We were pleased to report that Cumberland delivered a strong financial performance for the second quarter. Our line of FDA-approved brands delivered just under $10 million in net revenues, which represented 16% in sequential growth from the first quarter of the year. During the quarter...

Overall, the first quarter proved to be a productive start to the year. Our Cumberland team remains dedicated to our mission of working together to provide unique products that improve the quality of patient care. During the quarter, we shared a number of exciting company...

In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements. We took a fresh look at our mission statement during the year and refined it to better capture the spirit of...